Immunohistochemistry or IHC
Cytological Diagnosis of Malignant Mesothelioma: A Case Series
Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…
Read MoreNew candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin
Tissue & Cell 2022 September 6 [Link] Ozlem Ucer, Nevin Kocaman Abstract Objectives: Malignant mesothelioma (MM) is a primary malignant tumour with a very bad prognosis, which develops from the mesothelial cells lining the serosal surfaces. Because MM can show a wide variety of histological patterns and its cytomorphological features are quite extensive, it is…
Read MoreInvestigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods
Polish Journal of Pathology 2022 October 6 [Link] Fatma Sule Kutlar Dursun, Ulas Alabalik Abstract Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignant disease with a poor prognosis, which affects the surface mesothelium of the pleural cavity. Immune checkpoints are responsible for controlling the immune system to avoid autoimmunity and prevent tissue damage. In…
Read MoreEffects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy
Cancer Immunology, Immunotherapy 2022 September 17 [Link] Riki Okita, Yuka Mimura-Kimura, Nobutaka Kawamoto, Naoki Yamamoto, Masashi Umeda, Masanori Okada, Hidetoshi Inokawa, Yusuke Mimura, Tomoyuki Murakami, Masao Nakata, Kazunori Okabe Abstract Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity;…
Read MoreBrief Report: Multimodality Therapy in Patients with Primary Pericardial Mesothelioma
Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…
Read MoreHypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreTumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells
Thoracic Cancer 2022 August 2 [Link] Masayoshi Hasegawa, Yuki Hanamatsu, Chiemi Saigo, Yusuke Kito, Tamotsu Takeuchi Abstract Background: As mesothelioma generally has an unfavorable prognosis, further advances are needed to improve the outcomes in patients with mesothelioma. In the present study, we generated and characterized a monoclonal antibody that could inhibit mesothelioma cell proliferation in…
Read MoreSera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein
Journal of Oncology 2022 July 15 [Link] Elisa Mazzoni, Ilaria Bononi, John Charles Rotondo, Chiara Mazziotta, Roberta Libener, Roberto Guaschino, Roberta Gafà, Giovanni Lanza, Fernanda Martini, Mauro Tognon Abstract Malignant pleural mesothelioma (MPM), a fatal tumor, is mainly linked to the asbestos exposure. It has been reported that together with the inhalation of asbestos fibers,…
Read MoreClinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion
Biomedical Reports 2022 June 7 [Link] Guan-Ying Ma, Shuai Shi, Ping Wang, Xing-Guang Wang, Zhi-Gang Zhang Abstract The diagnostic value of the 9P21 gene determined using fluorescence in situ hybridization (FISH) combined with BRCA1-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) expression detection by immunohistochemistry, was investigated in serous effusion samples of malignant mesothelioma. A…
Read More